Dr. Allison Glasunow counsels innovative life sciences companies on patentability, portfolio development and global IP strategy to help protect and advance breakthrough technologies. She advises clients across the full innovation lifecycle—from early research and development through commercialization—guiding due diligence, freedom-to-operate and invalidity analyses, as well as providing substantive support in patent litigation matters.
Allison has deep technical experience spanning immunotherapy, peptide therapeutics, genetics and genomics, stem cells, pharmaceuticals, oncology, cardiovascular therapies, diagnostics and medical devices. Her work regularly involves cutting-edge biologic and therapeutic technologies, including cellular therapies such as CAR-T cells and induced pluripotent stem cells (iPSCs); antibodies, antibody-derived proteins and antibody-drug conjugates; peptide libraries; genome modification and gene-editing platforms; nucleic acid delivery technologies; and next-generation sequencing technologies.
Drawing on her scientific training and practical legal experience, Allison helps clients navigate complex technical and regulatory landscapes while building patent portfolios designed to withstand scrutiny from investors, acquirers and competitors. She is particularly focused on crafting forward-looking claim strategies that anticipate future product evolution, secondary indications and commercialization pathways.
Clients value Allison’s ability to translate complex scientific concepts into clear, commercially focused patent strategies. She is known for her collaborative approach and for partnering closely with clients to strengthen portfolio value in connection with fundraising, licensing, strategic transactions and long-term growth.
Outside of her legal practice, Allison enjoys spending time with her family and skiing in the mountains.